Notable 52-Week Highs and Lows of the Day 12/17: (BAC) (CX) (LUV) High; (END) (LNET) (TZYM) Low

December 17, 2012 2:04 PM EST Send to a Friend
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:
  • Bank of America Corp. (NYSE: BAC) $10.90. BofA and other financials ticking higher as lawmakers are nearing a consensus over the fiscal cliff. There is now just two weeks until about $600 billion of tax hikes and spending cuts kick in, which will largely have an adverse impact on the middle class.

    BofA moved as much as 3 percent higher Monday.

  • Cemex SAB (NYSE: CX) high of $9.59. Cemex making a strong move above the $9.50 level. Shares have been trending higher, but saw resistance at the $9.15 - $9.20 level.

  • Southwest Airlines Co. (NYSE: LUV) high of $10.43. Continuing higher after a positive outlook for the industry issued by the International Air Transport Association (IATA) last Thursday. Dahlman Rose also commented on recent performance in the segment, upgrading US Airways (NYSE: LCC) in the process.

  • Tesoro Corp (NYSE: TSO) high of $45.41. Tesoro continuing higher following affiliate Tesoro Logistics LP (NYSE: TLLP) moving to acquire Chevron assets last week. For more on the deal, click here.
52-Week Low:
  • Endeavour International Corp. (NYSE: END low of $4.89. Endeavour said purchase agreements to acquire ConocoPhillips’(NYSE: COP) interest in three producing U.K. oil fields in the Central North Sea were terminated. Global Hunter also downgraded the stock today. For more, click here.

  • LodgeNet Interactive (Nasdaq: LNET) low of $0.08. LodgeNet entered into an amended Forbearance Agreement agreement with lenders.

  • Tranzyme Pharma (Nasdaq: TZYM) low of $0.56. Tranzyme announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial.

    Shares slipped 35 percent today.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Bank of America

Add Your Comment